Login
$EVMN
$7.10 +$0.00 (0.0%) After hours

$EVMN SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 424B3
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Expanded pipeline with in-licensing of EVO570, a potential best-in-class oral VAV-1 molecular glue degrader

10 Nov 2026 SCHEDULE 13D/A
05 Nov 2026 8-K: Regulation FD Disclosure

Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader

04 Nov 2026 424B3
04 Nov 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 4, 2026, by and among Evommune, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an...

15 Oct 2026 Form 4: Pena Luis C., Director

Received 1,115 shares as a grant or award ($7.83K)

01 Oct 2026 8-K: Regulation FD Disclosure

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

23 Sep 2026 8-K: Regulation FD Disclosure

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress

15 Sep 2026 8-K: Regulation FD Disclosure

Evommune Corporate Presentation September 2026 © Evommune, Inc.

09 Sep 2026 424B3
09 Sep 2026 8-K: Regulation FD Disclosure; Other Events

‑ Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
06 Aug 2026 424B3
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026

30 Jul 2026 8-K: Regulation FD Disclosure

‑ MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support